These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26109913)

  • 1. Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance.
    López Torrecilla J; Hervás A; Zapatero A; Gómez Caamaño A; Macías V; Herruzo I; Maldonado X; Gómez Iturriaga A; Casas F; González San Segundo C
    Rep Pract Oncol Radiother; 2015; 20(4):259-72. PubMed ID: 26109913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology.
    Gómez-Caamaño A; González-San Segundo C; Henríquez I; Maldonado X; Zapatero A;
    Clin Transl Oncol; 2019 Apr; 21(4):420-432. PubMed ID: 30293231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corrigendum to "Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance". [Rep. Pract. Oncol. Radiother. 20 (2015) 259-272].
    López Torrecilla J; Hervás A; Zapatero A; Gómez Caamaño A; Macías V; Herruzo I; Maldonado X; Gómez Iturriaga A; Casas F; González San Segundo C
    Rep Pract Oncol Radiother; 2016; 21(1):90-2. PubMed ID: 26900365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
    Henríquez López I; González-San Segundo C; Vegas JO; Gutierrez C; Hervas A; Cabeza Rodriguez MÁ; Valero Albarrán J; Rodríguez Villalba S; Álvarez Gonzalez A; Sancho Pardo G; Zapatero A; Álvaro PC
    Radiother Oncol; 2019 Dec; 141():156-163. PubMed ID: 31570236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.
    Do T; Parker RG; Do C; Tran L; Do L; Dolkar D
    Cancer J Sci Am; 1998; 4(5):324-30. PubMed ID: 9815297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consensus statement on definition, diagnosis, and management of high-risk prostate cancer patients on behalf of the Spanish Groups of Uro-Oncology Societies URONCOR, GUO, and SOGUG.
    Henríquez I; Rodríguez-Antolín A; Cassinello J; Gonzalez San Segundo C; Unda M; Gallardo E; López-Torrecilla J; Juarez A; Arranz J
    Clin Transl Oncol; 2018 Mar; 20(3):392-401. PubMed ID: 28785912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate specific antigen only progression of prostate cancer.
    Moul JW
    J Urol; 2000 Jun; 163(6):1632-42. PubMed ID: 10799151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review.
    Artibani W; Porcaro AB; De Marco V; Cerruto MA; Siracusano S
    Urol Int; 2018; 100(3):251-262. PubMed ID: 29161715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
    Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
    Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
    Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
    Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definitions of biochemical failure in prostate cancer following radiation therapy.
    Taylor JM; Griffith KA; Sandler HM
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1212-9. PubMed ID: 11483331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer.
    Robnett TJ; Whittington R; Malkowicz SB; Brereton HD; Van Arsdalen K; Drach G; Wein AJ
    Int J Radiat Oncol Biol Phys; 2002 Aug; 53(5):1146-51. PubMed ID: 12128114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypofractionated radiotherapy as salvage for rising prostate-specific antigen after radical prostatectomy.
    Lee LW; McBain CA; Swindell R; Wylie JP; Cowan RA; Logue JP
    Clin Oncol (R Coll Radiol); 2004 Dec; 16(8):517-22. PubMed ID: 15630843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical disease-free survival in localized carcinoma of prostate treated with external beam irradiation: comparison of American Society of Therapeutic Radiology and Oncology Consensus or 1 ng/mL as endpoint.
    Perez CA; Michalski JM; Lockett MA
    Int J Radiat Oncol Biol Phys; 2001 Apr; 49(5):1287-96. PubMed ID: 11286836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy.
    Kang YJ; Jang WS; Kwon JK; Yoon CY; Lee JY; Ham WS; Choi YD
    BMC Cancer; 2017 Nov; 17(1):789. PubMed ID: 29169347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion--"nadir + 2"?
    Nielsen ME; Makarov DV; Humphreys E; Mangold L; Partin AW; Walsh PC
    Urology; 2008 Aug; 72(2):389-93; discussion 394-5. PubMed ID: 18279937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy?
    Koppie TM; Grossfeld GD; Nudell DM; Weinberg VK; Carroll PR
    J Urol; 2001 Jul; 166(1):111-5. PubMed ID: 11435834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.
    Pearse M; Fraser-Browne C; Davis ID; Duchesne GM; Fisher R; Frydenberg M; Haworth A; Jose C; Joseph DJ; Lim TS; Matthews J; Millar J; Sidhom M; Spry NA; Tang CI; Turner S; Williams SG; Wiltshire K; Woo HH; Kneebone A
    BJU Int; 2014 Mar; 113 Suppl 2():7-12. PubMed ID: 24894850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.